PBS Information: Emergency Drug (Doctor’s Bag) Supply only.
For emergency pain in patients with trauma.
Penthrox is not listed on the PBS for pain relief during surgical procedures.

MINIMUM PRODUCT INFORMATION – Penthrox® (methoxyflurane) Inhalation

INDICATIONS: For emergency relief of pain by self administration in conscious haemodynamically stable patients with trauma and associated pain, under supervision of personnel trained in its use and for the relief of pain in monitored conscious patients who require analgesia for surgical procedures such as the change of dressings. CONTRAINDICATIONS: Use as an anaesthetic agent; renal impairment; renal failure; hypersensitivity to fluorinated anaesthetics (including familial history of hypersensitivity) or any ingredients in Penthrox®; cardiovascular instability; respiratory depression; head injury or loss of consciousness; malignant hyperthermia. PRECAUTIONS: Not to be used as an anaesthetic agent; liver disease and liver damage after previous methoxyflurane or halothane anaesthesia; diabetic patients (may have an increased likelihood of developing nephropathy); paediatric patients (minimum effective dose should be administered); use in pregnancy and lactation, the elderly and regular exposure to health workers. INTERACTIONS: Antibiotics including tetracycline, gentamicin, kanamycin, colistin, polymyxin B, cephaloridine and amphotericin B; subsequent narcotics administration; concomitant use with CNS depressants (e.g opioids); treatment with enzyme inducing drugs (e.g. barbiturates); cautious use of adrenaline or nor-adrenaline during methoxyflurane administration; β-blockers. ADVERSE EFFECTS: Very common: Dizziness, headache; Common: Dry mouth, nausea, toothache, vomiting, feeling drunk, influenza, nasopharyngitis, viral infection, fall, joint sprain, increase alanine aminotransferase, increase aspartate aminotransferase, increase blood lactate dehydrogenase, back pain, amnesia, dysarthria, migraine, somnolence, dysmenorrhoea, cough, oropharyngeal pain, rash, hypotension, euphoria, diaphoresis, dysgeusia, flushing, hypertension, anxiety, depression, sensory neuropathy, confusion, musculoskeletal. DOSAGE AND ADMINISTRATION: One 3 mL bottle vaporised in a Penthrox® Inhaler. Up to 6 mL may be administered per day. The total weekly dose should not exceed 15 mL. Administration on consecutive days is not recommended.

Product Information is available from 1800 PENTHROX (1800 736 847) or www.medicaldev.com/penthrox-pi. Date prepared: 27 November 2018
(PI amended 13 December 2019).

Penthrox® is a registered trademark of Medical Developments International Limited. ABN 14 106 340 667. 4 Caribbean Drive, Scoresby, Victoria 3179. www.medicaldev.com. Mundipharma PTY Limited. ABN 87 081 322 509. 88 Phillip Street, Sydney, NSW 2000. Tel: (02) 9391 7200. ORBIS AU-5670.
June 2020.